Clinical Uses of Medroxyprogesterone Acetate
Medroxyprogesterone acetate (MPA) is primarily indicated for contraception, with the injectable depot formulation (DMPA) being the most widely used form for pregnancy prevention, administered every 3 months. 1
Primary Indication: Contraception
Injectable DMPA (Depot Medroxyprogesterone Acetate)
- DMPA is FDA-approved solely for contraception, with intramuscular (IM) administration of 150 mg every 13 weeks being the standard regimen 1
- The 12-month failure rate ranges from 0% to 0.7%, making it one of the most effective contraceptive methods available 1
- Subcutaneous DMPA (DMPA-SC) at 104 mg/0.65 mL is now recommended as an additional delivery approach, including for self-administration, which enhances reproductive autonomy and contraceptive access 2
- Self-administered DMPA-SC should be offered through shared decision-making, with provider-administered options remaining available 2
Mechanism and Administration
DMPA works by inhibiting gonadotropin secretion, preventing follicular maturation and ovulation, while also causing endometrial thinning 1. The medication has an approximate 50-day half-life, with contraceptive effects lasting well beyond the 13-week dosing interval 1. Reinjections can be given up to 2 weeks late (15 weeks from last injection) without requiring backup contraception 2.
Secondary/Off-Label Therapeutic Uses
Endometriosis Management
Oral MPA at 50 mg daily for 4 months effectively treats endometriosis symptoms, with 80% of patients showing improvement in pain, pelvic nodularity, and tenderness 3. The medication induces pseudodecidualized reaction and atrophic changes in both normal endometrium and ectopic implants, while suppressing ovulation and reducing LH and estradiol levels 3. DMPA-SC also demonstrates efficacy for endometriosis with minimal bone density changes over 6 months 4.
Menstrual Cycle Regulation in PCOS
MPA at 10 mg for 10 days per month provides good menstrual cycle control in women with polycystic ovary syndrome (PCOS) 5. Treatment significantly decreases luteinizing hormone, total testosterone, and free androgen index, while improving acne and seborrhea scores, without adversely affecting lipid or carbohydrate metabolism 5.
Ovarian Stimulation Protocol
MPA serves as an oral alternative to GnRH antagonists for preventing premature LH surges during controlled ovarian hyperstimulation for IVF 6. When combined with hMG starting on cycle day 3, MPA maintains LH suppression with only 0.7% incidence of premature LH surge, yielding comparable pregnancy outcomes to traditional protocols when embryos are cryopreserved 6.
Additional Noncontraceptive Benefits
Evidence supports that DMPA use is associated with:
- Reduced iron-deficiency anemia
- Protection against pelvic inflammatory disease
- Protection from endometrial cancer
- Improved hematologic parameters in women with sickle cell disease 7
Important Safety Considerations and Caveats
Bone Mineral Density
The loss of bone mineral density should be considered in the risk/benefit assessment, particularly for adolescents and women using DMPA long-term 1. However, studies show no differences in bone density changes between DMPA-SC and DMPA-IM at 2 years 4.
Meningioma Risk - Critical Recent Finding
A 2025 study identified increased meningioma risk with depot MPA (relative risk 2.43), particularly with exposures longer than 4 years or when started after age 31 8. The number needed to harm is 1,152 patients for depot MPA and 3,020 for oral MPA, suggesting low absolute clinical risk but warranting informed consent for long-term users 8. This risk was not observed with other contraceptive methods 8.
Postmenopausal Hormone Therapy
When used with conjugated equine estrogens for postmenopausal hormone therapy, MPA may increase risks of breast cancer, stroke, and cognitive decline in older women 9. However, short-term use (less than 5 years) immediately after menopause for vasomotor symptoms does not appear to carry increased risk 9.
Bleeding Management
For DMPA users experiencing irregular bleeding, NSAIDs for 5-7 days may be offered as treatment 10. Reassurance should be provided that bleeding irregularities are common and not medically concerning, with the option to discontinue at any time 10.
Return to Fertility
Women with lower body weights conceive sooner than those with higher body weights after discontinuing DMPA 1. This should be discussed during contraceptive counseling.